These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17364114)

  • 21. Provisional stenting for multivessel PCI.
    Han B; Liu L; Aboud M; Nahir M; Hasin Y
    Int J Cardiovasc Intervent; 2005; 7(1):46-51. PubMed ID: 16019615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study.
    Sels JW; Tonino PA; Siebert U; Fearon WF; Van't Veer M; De Bruyne B; Pijls NH
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1183-9. PubMed ID: 22115657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C; Sesana M; Leonzi O; Cuccia C
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
    Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
    Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention.
    Jensen LO; Kaltoft A; Thayssen P; Tilsted HH; Christiansen EH; Mikkelsen KV; Maeng M; Hansen KN; Villadsen AB; Madsen M; Lassen JF; Pedersen KE; Thuesen L
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):101-8. PubMed ID: 19670299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
    Dangas GD; Caixeta A; Mehran R; Parise H; Lansky AJ; Cristea E; Brodie BR; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Möeckel M; Stone GW;
    Circulation; 2011 Apr; 123(16):1745-56. PubMed ID: 21482968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
    Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
    Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention.
    Okmen E; Sanli A; Uyarel H; Dayi S; Tartan Z; Cam N
    Angiology; 2006; 57(3):273-81. PubMed ID: 16703187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?
    Piamsomboon C; Wong PM; Mathur A; Singh D; Liu MW; Baxley WA; Iyer SS; Dean LS; Roubin GS
    Catheter Cardiovasc Interv; 1999 Apr; 46(4):415-20. PubMed ID: 10216005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of unstable coronary syndromes in patients with previous coronary artery bypass grafts following coronary angiography.
    Chan AW; Ross J
    Clin Invest Med; 1997 Oct; 20(5):320-6. PubMed ID: 9336657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of enoxaparin and unfractionated heparin in coronary angioplasty.
    Korovesis S; Karvouni E; Karabinos I; Giazitzoglou E; Papadopoulos A; Katritsis D
    Hellenic J Cardiol; 2005; 46(1):46-51. PubMed ID: 15807395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early aggressive treatment of unstable angina without on-site cardiac surgical facilities: a prospective study of acute and long-term outcome.
    Ferrero V; Steffenino G; Meinardi F; Conte E; Deorsola A; Vado A; Racca E; Dellavalle A; Ribichini F; Menardi E; Uslenghi E
    G Ital Cardiol; 1998 Feb; 28(2):112-9. PubMed ID: 9534050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial).
    Nikolsky E; Kosinski E; Mishkel GJ; Kimmelstiel C; McGarry TF; Mehran R; Leon MB; Russell ME; Ellis SG; Stone GW
    Am J Cardiol; 2005 Mar; 95(6):709-15. PubMed ID: 15757595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography.
    Gonzalo N; Barlis P; Serruys PW; Garcia-Garcia HM; Onuma Y; Ligthart J; Regar E
    JACC Cardiovasc Interv; 2009 May; 2(5):445-52. PubMed ID: 19463469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute and long term results of unprotected left main stenting using drug eluting stents.
    Tzifos V; Gatsis A; Gerasimou A; Chatzis D; Theodorakis G
    Cardiol J; 2011; 18(2):165-70. PubMed ID: 21432823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current patterns of antithrombotic and revascularisation therapy in patients hospitalised for acute coronary syndromes. Data from the Polish subset of the EPICOR study.
    Wojtkowska I; Stępińska J; Stępień-Wojno M; Sobota M; Kopaczewski J; Reszka Z; Kurzelewski M; Medina J
    Kardiol Pol; 2017; 75(5):445-452. PubMed ID: 28281731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.